• GLT-1–CB1–CREB Signaling in TBI

  2026-08-16

  A 2025 Biomolecules study identifies a mechanistic link between post-traumatic 2-arachidonoylglycerol accumulation, CB1–CREB signaling, and loss of astrocytic GLT-1. Its mouse controlled cortical impact experiments connect impaired glutamate clearance with neuronal apoptosis and cognitive dysfunction, while pharmacological CB1 blockade supports GLT-1 preservation as a potential neuroprotective strategy.

• AMPK–SQSTM1 Feedback Loop in Metabolic Stress

  2026-08-15

  The 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates AMPK and NFE2L2/NRF2 activation during metabolic stress. Its mechanistic framework links lysosomal deacidification, TAK1-dependent p62 phosphorylation, KEAP1 degradation, and antioxidant adaptation, offering a clearer explanation of stress tolerance in STK11/LKB1- and KEAP1-altered lung cancer contexts.

• DMG-PEG2000-NH2: LNP Linker Workflow

  2026-08-15

  DMG-PEG2000-NH2 combines a lipid-compatible DMG anchor with a reactive primary amine for controlled bioconjugation in liposomes and lipid nanoparticles. This workflow-focused guide covers amide coupling, siRNA encapsulation support, assay selection, and troubleshooting without overstating evidence from unrelated drug-discovery studies.

• Azilsartan medoxomil monopotassium in Cell Assays

  2026-08-14

  A scenario-based guide to using Azilsartan medoxomil monopotassium (SKU B1071) in receptor, viability, proliferation, and cytotoxicity workflows. It connects formulation, concentration, washout, vehicle control, and interpretation decisions to published pharmacology and practical laboratory constraints.

• S63845 MCL1 Inhibitor: Apoptosis Workflow

  2026-08-14

  Build a mechanism-first apoptosis workflow around S63845, from MCL1-dependent cell screening to cytochrome c, caspase, and mitochondrial readouts. The approach distinguishes direct MCL1 blockade from inner-membrane remodeling, helping researchers interpret selective cytotoxicity in hematological cancer models.

• SR-202 in PPARγ Pathway Research

  2026-08-13

  SR-202 provides a selective pharmacological switch for testing how PPARγ controls adipocyte differentiation, macrophage polarization, and metabolic inflammation. This workflow-oriented guide connects the compound to insulin resistance research, obesity research, and pathway validation while separating published evidence from practical starting conditions.

• Olive Oil Polyphenols and Cardiovascular Protection

  2026-08-13

  The reference study shows that extra virgin olive oil polyphenol concentration influences antioxidant, anti-inflammatory, and cholesterol-efflux activity in cellular models. Its comparison of standard and naturally high-phenolic extracts with hydroxytyrosol and tyrosol provides a useful framework for interpreting composition, dose, and mechanism in cardiovascular health research.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance

  2026-08-12

  The reference study identifies RCN2 as a mechanistic driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent degradation of PPP2CA and activation of PI3K-AKT signaling. Its integrated clinical, proteomic, biochemical, cellular, and animal-model evidence provides a framework for studying how protein turnover links metastatic progression with treatment failure.

• Mitomycin C as a Probe of Tumor DNA-Repair Resistance

  2026-08-12

  Mitomycin C is an antitumor antibiotic that can do more than induce cytotoxicity: it can function as a mechanistic stress test for tumor DNA-repair and apoptosis phenotypes. This article connects its DNA damage activity with SCUBE3-driven therapy resistance and translates that connection into practical assay decisions.

• In Vitro Drug Response: Arrest Versus Cell Death

  2026-08-11

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that drug-induced growth inhibition and cell death are related but non-equivalent response dimensions. The framework supports more precise assay interpretation by requiring researchers to consider response magnitude, mechanism, and timing rather than treating a single viability endpoint as a complete measure of drug efficacy.

• GM 6001 (Galardin) in Cell Assays

  2026-08-10

  This scenario-driven guide explains how GM 6001 (Galardin), SKU A4050, can improve interpretation of viability, proliferation, and extracellular-matrix assays. It covers mechanism, controls, DMSO stock preparation, data interpretation, and practical supplier-selection criteria.

• Removing Pollen Interference in EEM Bioaerosol Analysis

  2026-08-09

  The reference study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosol components, but targeted spectral transformations combined with random forest modeling can substantially improve discrimination. Its strongest practical contribution is a nuisance-aware workflow that raises classification accuracy while preserving recognition of important bacterial and toxin targets.

• Carboxylesterase Confounds Mitochondrial H2O2 Assays

  2026-08-08

  The reference study showed that carboxylesterases can convert Amplex Red to resorufin without hydrogen peroxide, horseradish peroxidase, or oxygen, challenging a common interpretation of mitochondrial H2O2 release assays. Its inhibitor controls and correction strategies provide a practical framework for distinguishing genuine reactive oxygen species signals from matrix-dependent probe conversion.

• HyperFluor 488 Goat Anti-Mouse IgG in ATII Assays

  2026-08-07

  Learn how to use this fluorescently labeled secondary antibody to visualize DRP1-associated mitochondrial remodeling in ATII cells and extend the same mouse-primary workflow to flow cytometry and western blotting. Practical dilution, control, storage, and troubleshooting guidance helps separate true biological signal from secondary-antibody background.

• CHIR 99021 Trihydrochloride: GSK-3 Inhibitor for Organoid In

  2026-08-07

  CHIR 99021 trihydrochloride is redefining organoid and stem cell workflows by enabling precise control over self-renewal and differentiation. Its proven selectivity and potency as a GSK-3 inhibitor unlock advanced experimental designs for insulin signaling, disease modeling, and scalable high-throughput studies.

455 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page